Abstract:AIM: TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) has been reported to specifically induce apoptosis of cancer cells although only a small percentage of cell lines were sensitive to it. Cell lines not responding to TRAIL in vitro were said to be more prone to apoptosis when TRAIL was combined with another anticancer agent. Generally, factors affecting drug-sensitivity involve many apoptosis-related proteins, including p53. The expression of wild-type p53 gene was proposed as an important premise for tumor cells responding to chemotherapy. The present study was to investigate the cell killing action of TRAIL on colon cancer cell line SW480, its synergistic effect with doxorubicin, and the possible mechanisms. METHODS: SW480 cells were cultured in the regular condition and incubated with different levels of agents. Morphologic changes in these cells after treatment were observed under phase-contrast microscope and cytotoxicity by TRAIL alone and in combination with doxorubicin was quantified by a 1-day microculture tetrazolium dye (MTT) assay. In addition, flow cytometry assay (FCM) and transmission electron microscopy were used to detect apoptosis among these cells. Variation of p53 protein level among different groups according to concentrations of agents was measured by Western blot assay. RESULTS: (1) SW480 cells were not sensitive to TRAIL, with IC50>1 mg.L-1 and dose-independent cytotoxicity. (2) SW480 cells were sensitive to doxorubicin at a certain degree, with dose-dependent cytotoxicity and IC50 = 65.25 +/- 3.48 mumol.L-1. (3) TRAIL could synergize with doxorubicin to kill SW480 cells effectively, which was represented by the boosted killing effect of doxorubicin on theses cells. IC50 of doxorubicin against SW480 cells sharply reduced when it was combined with TRAIL. (4) Subtoxic TRAIL (100 mug.L-1), combined with subtoxic doxorubicin (0.86 mumol.L-1), could kill SW480 cells sufficiently. Cytotoxicity by MTT assay arrived at 80.12 +/- 2.67%, which was significantly higher than that by TRAIL or doxorubicin alone, with P = 0.006 and 0.003 respectively. This killing effect was partly due to apoptosis. It was proved by large amounts of apoptotic cells under phase-contrast microscopy, cell apoptosis rate of 76.82 +/- 1.93% by FCM assay and typical apoptotic morphology observed through transmission electron microscopy. Increase of apoptosis after combined treatment had no relation with protein level of p53 (P > 0.05). CONCLUSION: SW480 cells are not sensitive to TRAIL, but TRAIL can synergize with lower concentration of doxorubicin to induce apoptosis effectively. The status of p53 protein is not involved in the mechanism of synergistic apoptosis. It suggests the potential therapeutic applicability of the combination of TRAIL with doxorubicin against colon cancers.

Use of p38 MAPK inhibitor reduces resistance of colon cancer cells to doxorubicin

The application P38 inhibitor reduces the AKT expression in colon cancer cell line

Inhibition of the P38 Mapk Pathway Sensitizes Human Gastric Cells to Doxorubicin Treatment in Vitro and in Vivo

Inhibition of P38 MAPK Diminishes Doxorubicin-Induced Drug Resistance Associated with P-glycoprotein in Human Leukemia K562 Cells

Role Of P38 Mapk In Enhanced Human Cancer Cells Killing By The Combination Of Aspirin And Abt-737

Isofraxidin Inhibited Proliferation and Induced Apoptosis Via Blockage of Akt Pathway in Human Colorectal Cancer Cells

Effect of p38 MAPK on the Expression of P-glycoprotein in Multidrug Resistant K562

Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.

Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance Through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type P53 Multidrug-resistant Breast Cancer Cells

Synergistic Effect of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) and Doxorubicin on Human Colon Cancer SW480 Cells

Chemoresistance To Doxorubicin Induces Epithelial-Mesenchymal Transition Via Upregulation Of Transforming Growth Factor Signaling In Hct116 Colon Cancer Cells

Inhibition of P38 MAPK Increases the Sensitivity of 5-Fluorouracil-resistant SW480 Human Colon Cancer Cells to Noscapine

[Inhibition of Autophagy Enhances Apoptosis Induced by Doxorubicin Hydrochloride in Human Colon Cancer Cells].

Study the Relationship Between MiR-19 Antisense Oligonucleotides and the Sensitivity of CD133+ HT29 Cell Subsets to Doxorubicin

Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells.

Reversal Effect of Inhibiting or Silencing the Expression of Akt Gene on Hydroxycampothecin-Resistance of Colorectal Cancer SW1116/HCPT Cells

B7-H3 suppresses doxorubicin-induced senescence-like growth arrest in colorectal cancer through the AKT/TM4SF1/SIRT1 pathway

Effect of STAT3/AKT signal pathway in resistance of colon cancer cells to cisplatin

Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells

Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway

Pharmacological Inhibition Of P38 Mapk By Sb203580 Increases Resistance To Carboplatin In A2780cp Cells And Promotes Growth In Primary Ovarian Cancer Cells